A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting

被引:7
|
作者
Xu, Ben [1 ]
Li, Gonghui [2 ]
Kong, Chuize [3 ]
Chen, Ming [4 ]
Hu, Bin [5 ]
Jiang, Qing [6 ]
Li, Ningchen [7 ]
Zhou, Liqun [1 ]
机构
[1] Peking Univ, Peking Univ Hosp 1, Dept Urol, Inst Urol,Natl Urol Canc Ctr, 8 Xishiku St, Beijing 100034, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Urol, Sch Med, Hangzhou, Peoples R China
[3] China Med Univ, Dept Urol, Hosp 1, Shenyang, Peoples R China
[4] Southeast Univ, Dept Urol, Affiliated Zhongda Hosp, Nanjing, Peoples R China
[5] China Med Univ, Liaoning Canc Hosp & Inst, Dept Urol, Canc Hosp, Shenyang, Peoples R China
[6] Chongqing Med Univ, Dept Urol, Affiliated Hosp 2, Chongqing, Peoples R China
[7] Peking Univ, Hlth Sci Ctr, Dept Urol, Shougang Hosp, Beijing, Peoples R China
关键词
Prostate cancer; prostate biopsy; prostate specific antigen; risk prediction; MP-MRI; MULTIPARAMETRIC MRI; DIAGNOSTIC-ACCURACY; RISK CALCULATOR; COMPARING; 6; PREDICTION; IMPACT; CHINA; MODEL; MEN;
D O I
10.1080/03007995.2021.1949270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective This study aimed to evaluate the predictors for positive biopsy in prostate cancer (PCa) patients and develop a risk-stratification score model for positive biopsy rate in patients with prostate specific antigen (PSA) in the gray zone. Methods In this retrospective, multicenter, real-world study, Chinese patients receiving prostate biopsy for the first time were included. The study evaluated the positive biopsy rate, predictors for positive biopsy and a risk prediction model for PSA 4-10 ng/mL PCa was developed. The univariate and multivariate logistic regression analyses were used to identify the risk factors. Results A total of 2426 patients were included in the study. The biopsy positive rate was 47.57%, 25.77%, and 60.57% among overall patients, total PSA (t-PSA) 4-10 ng/mL patients, and PSA > 10 ng/mL patients respectively. Elderly age 60-74, >= 75, multi parametric magnetic resonance imaging (MP-MRI), pre-operative PSA > 10 and PSA density (PSAD) significantly increased the positive rate in overall population, and elderly age, MP-MRI, positive digital rectal examination and f-PSA were significant predictors for positive biopsy in PSA 4-10 ng/mL population. A risk prediction model for positive biopsy rate in patients with PSA in the gray zone was developed. Area under curve (AUC) was associated with low accuracy for all the variables used such as tPSA (0.53), PSAD (0.57), frequency of puncture (0.53) and MP-MRI (0.64) in prediction of biopsy positive rate. Conclusion Our study evaluated the significant predicative factors for positive biopsy and the PCa risk prediction model developed might help Clinicians to avoid unnecessary biopsy in patients with PSA in gray zone.
引用
收藏
页码:1617 / 1625
页数:9
相关论文
共 50 条
  • [21] Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population
    Legisi, Lorena
    DeSa, Elise
    Qureshi, M. Nasar
    AMERICAN HEALTH AND DRUG BENEFITS, 2016, 9 (09) : 497 - 502
  • [22] The Impact of Prostate Volume on the Prostate Imaging and Reporting Data System (PI-RADS) in a Real-World Setting
    Volz, Yannic
    Apfelbeck, Maria
    Pyrgidis, Nikolaos
    Pfitzinger, Paulo L.
    Berg, Elena
    Ebner, Benedikt
    Enzinger, Benazir
    Ivanova, Troya
    Atzler, Michael
    Kazmierczak, Philipp M.
    Clevert, Dirk-Andre
    Stief, Christian
    Chaloupka, Michael
    DIAGNOSTICS, 2023, 13 (16)
  • [23] Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study
    LI, Jian-ri
    Wang, Shian-shiang
    Chen, Chuan-shu
    Yang, Cheng-kuang
    Lu, K. E. V. I. N.
    Cheng, Chen-Li
    Hung, Sheng-Chun
    Chen, Shu-Yen
    Hsu, Chiann Yi
    Chiu, Kun-Yuan
    ANTICANCER RESEARCH, 2022, 42 (10) : 4857 - 4866
  • [24] Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients
    Sanchez, Julian Cordoba
    Picola, Natalia
    Rodriguez-Vida, Alejo
    Costa, Marc
    Castaneda, David Marmolejo
    Marquez, Meritxell Perez
    Rodriguez, Jesus Munoz
    Gaya, J. M.
    Bravo, Alejandra
    Buisan, Oscar
    Servian, Pol
    Suarez, Jose Francisco
    Felip, Mireia Musquera
    Caparros, Maria Jose Ribal
    Asensio, Antonio Alcaraz
    Vilaseca, Antoni
    CANCER MEDICINE, 2023, 12 (24): : 21969 - 21977
  • [25] A positive real-time elastography is an independent marker for detection of high-risk prostate cancers in the primary biopsy setting
    Nygard, Yngve
    Haukaas, Svein A.
    Halvorsen, Ole J.
    Gravdal, Karsten
    Frugard, Jannicke
    Akslen, Lars A.
    Beisland, Christian
    BJU INTERNATIONAL, 2014, 113 (5B) : E90 - E97
  • [26] Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study
    Gladstone, Jonathan
    Chhibber, Sameer
    Minhas, Jagdeep
    Neish, Calum S.
    Power, G. Sarah
    Lan, Zhiyi
    Rochdi, Driss
    Lanthier-Martel, Jessica
    Bastien, Natacha
    HEADACHE, 2022, 62 (01): : 78 - 88
  • [27] Variables Associated with False-Positive PSA Results: A Cohort Study with Real-World Data
    Lumbreras, Blanca
    Anne Parker, Lucy
    Pablo Caballero-Romeu, Juan
    Gomez-Perez, Luis
    Puig-Garcia, Marta
    Lopez-Garrigos, Maite
    Garcia, Nuria
    Hernandez-Aguado, Ildefonso
    CANCERS, 2023, 15 (01)
  • [28] Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study
    Salfi, Giuseppe
    Pedrani, Martino
    Candan, Selin
    Urechie, Vasile
    Merler, Sara
    Ruinelli, Lorenzo
    Colombo, Amos
    Castelo-Branco, Luis
    Testi, Irene
    Turco, Fabio
    Tortola, Luigi
    Vogl, Ursula
    Gabutti, Luca
    Gillessen, Silke
    Mestre, Ricardo Pereira
    EUROPEAN UROLOGY OPEN SCIENCE, 2025, 71 : 1 - 10
  • [29] Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study
    Hyvakka, Anniina
    Kaariainen, Okko-Sakari
    Utriainen, Tapio
    Loyttyniemi, Eliisa
    Mattila, Kalle
    Reinikainen, Petri
    Sormunen, Jorma
    Jaaskelainen, Minna
    Auvinen, Paivi
    Minn, Heikki
    Sundvall, Maria
    CANCER MEDICINE, 2023, 12 (04): : 4064 - 4076
  • [30] Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
    Gacci, Mauro
    Marchioni, Michele
    De Francesco, Piergustavo
    Natoli, Clara
    Calabro, Fabio
    Losanno, Tania
    Gianmartin, Cito
    Serni, Sergio
    Doni, Laura
    De Nunzio, Cosimo
    De Tursi, Michele
    Valeriani, Maurizio
    Giacinti, Silvana
    Alvarez-Maestro, Mario
    Scarcia, Marcello
    Ludovico, Giuseppe M.
    Del Bene, Gabriella
    Simone, Giuseppe
    Ferriero, Mariaconsiglia
    Tuderti, Gabriele
    Bove, Pierluigi
    Laudisi, Anastasia
    Carrieri, Giuseppe
    Cormio, Luigi
    Verze, Paolo
    La Rocca, Roberto
    Falsaperla, Mario
    Frantellizzi, Viviana
    Greco, Francesco
    Di Nicola, Marta
    Schips, Luigi
    Cindolo, Luca
    MINERVA UROLOGY AND NEPHROLOGY, 2021, 73 (04): : 489 - 497